Intervention not reported
Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).
1 finding from 1 review
Intervention not reported
IMDC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (OS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Blood transfusion · Percutaneous nephrolithotomy
Topical TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in thromboembolic events compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Adverse event · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in adverse event compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Topical TXA showed no clear difference in major surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Minor surgical complications · Percutaneous nephrolithotomy
Topical TXA may leads to lower minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Unplanned hospitalizations or readmissions · Percutaneous nephrolithotomy
1 finding from 1 review
Length of hospital stay · Percutaneous nephrolithotomy
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
1 finding from 1 review
Adverse events · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in adverse events compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in secondary interventions compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower major surgical complications compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Minor surgical complications · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review